Literature DB >> 33569666

Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.

Rahul S Dalal1,2,3, Ashwin N Ananthakrishnan4,2, Matthew J Hamilton1,2,3, Rachel W Winter5,6,7.   

Abstract

Entities:  

Keywords:  Anti-TNF; Biologic; Inflammatory bowel diseases; Non-responder; Remission; Ulcerative colitis; Ustekinumab

Year:  2021        PMID： 33569666     DOI： 10.1007/s10620-021-06852-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  22 in total

1.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

3.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

4.  Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients.

Authors:  Silvo Koder; Katja Repnik; Ivan Ferkolj; Cvetka Pernat; Pavel Skok; Rinse K Weersma; Uroš Potočnik
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

Review 5.  Innate and adaptive immunity in inflammatory bowel disease.

Authors:  Alessandra Geremia; Paolo Biancheri; Philip Allan; Gino R Corazza; Antonio Di Sabatino
Journal:  Autoimmun Rev       Date:  2013-06-15       Impact factor: 9.754

6.  Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.

Authors:  Margaux Welty; Laura Mesana; Amie Padhiar; Dominik Naessens; Joris Diels; Suzy van Sanden; Maud Pacou
Journal:  Curr Med Res Opin       Date:  2020-01-29       Impact factor: 2.580

Review 7.  First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.

Authors:  Siddharth Singh; Mohammad Hassan Murad; Mathurin Fumery; Parambir S Dulai; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-13       Impact factor: 11.382

8.  A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1.

Authors:  Jochen Hampe; Andre Franke; Philip Rosenstiel; Andreas Till; Markus Teuber; Klaus Huse; Mario Albrecht; Gabriele Mayr; Francisco M De La Vega; Jason Briggs; Simone Günther; Natalie J Prescott; Clive M Onnie; Robert Häsler; Bence Sipos; Ulrich R Fölsch; Thomas Lengauer; Matthias Platzer; Christopher G Mathew; Michael Krawczak; Stefan Schreiber
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

9.  NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.

Authors:  Jan Hendrik Niess; Jochen Klaus; Johannes Stephani; Carolin Pflüger; Nadine Degenkolb; Ulrike Spaniol; Benjamin Mayer; Georgia Lahr; Georg B T von Boyen
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

10.  Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.

Authors:  Remo Panaccione; Silvio Danese; William J Sandborn; Christopher D O'Brien; Yiying Zhou; Hongyan Zhang; Omoniyi J Adedokun; Ilia Tikhonov; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Ellen J Scherl; Rupert W Leong; David S Rowbotham; Ramesh P Arasaradnam; Bruce E Sands; Colleen Marano
Journal:  Aliment Pharmacol Ther       Date:  2020-10-21       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.